Embargoed access to the paper and contact details for authors are available in Notes to Editors at the end of the release.
- By 2050, over three-quarters (155 of 204) of countries will not have high enough fertility rates to sustain population size over time; this will increase to 97% of countries (198 of 204) by 2100.
- Pronounced shifts in patterns of livebirths are also predicted, with the share of the world’s live births nearly doubling in low-income regions from 18% in 2021 to 35% in 2100; and sub-Saharan Africa accounting for one in every two children born on the planet by 2100.
- In low-income settings with higher fertility rates, better access to contraceptives and female education will help reduce birth rates, while in low-fertility, high-income economies, policies that support parents and open immigration will be vital to maintain population size and economic growth.
- Authors warn that national governments must plan for emerging threats to economies, food security, health, the environment, and geopolitical security brought on by these demographic changes that are set to transform the way we live.
**For regional and individual-level country data, see notes to editors**
The world is approaching a low-fertility future. Although by 2100 more than 97% of countries and territories will have fertility rates below what is necessary to sustain population size over time, comparatively high fertility rates in numerous low-income countries, predominantly in western and eastern sub-Saharan Africa, will continue to drive population increases in these locations throughout the century. This ‘demographically divided world’ will have enormous consequences for economies and societies, according to a new study published in The Lancet.
The research presents estimates from the Global Burden of Disease, Injuries, and Risk Factors Study (GBD) 2021 – a global research effort led by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington’s School of Medicine – for past, current, and future global, regional, and national trends in fertility and live births. In general, countries need to have a total fertility rate (TFR) of 2.1 children per person who could give birth, to sustain long-term generational replacement of the population. The TFR of a population is the average number of children that are born to a female over a lifetime, assuming childbearing at current fertility rates throughout the reproductive years.
Using novel methods for forecasting mortality, fertility, key drivers of fertility (e.g., level of education, unmet need for modern contraception, child mortality, and living in urban areas), and livebirths, the researchers estimate that by 2050, 155 of 204 (76%) countries and territories will be below the replacement level of fertility. The number of countries and territories below replacement level is predicted to further increase to 198 of 204 (97%) by 2100. This means that in these locations, populations will shrink unless low fertility can be offset by ethical and effective immigration. The extent of low fertility may also be mitigated in part by policies that offer greater support for parents.
The new fertility forecasts underscore the enormous challenges to economic growth in many middle- and high-income countries with a dwindling workforce and the growing burden on health and social security systems of an ageing population.
The new study also predicts huge shifts in the global pattern of livebirths from higher- to lower-income countries. In 2021, 29% of the world’s babies were born in sub-Saharan Africa; by 2100, this is projected to rise to over half (54%) of all babies, emphasizing the urgency for improvements in access to modern contraception and female education in these countries.
“We are facing staggering social change through the 21st century,” said senior author Professor Stein Emil Vollset from IHME. "The world will be simultaneously tackling a 'baby boom' in some countries and a 'baby bust' in others. As most of the world contends with the serious challenges to the economic growth of a shrinking workforce and how to care for and pay for ageing populations, many of the most resource-limited countries in sub-Saharan Africa will be grappling with how to support the youngest, fastest-growing population on the planet in some of the most politically and economically unstable, heat-stressed, and health system-strained places on earth.”
“The implications are immense,” said co-lead author and Lead Research Scientist from IHME Dr. Natalia V. Bhattacharjee. “These future trends in fertility rates and live births will completely reconfigure the global economy and the international balance of power and will necessitate reorganizing societies. Global recognition of the challenges around migration and global aid networks are going to be all the more critical when there is fierce competition for migrants to sustain economic growth and as sub-Saharan Africa’s baby boom continues apace.”
Declining fertility worldwide – only six countries with fertility rates above replacement level in 2100
The global TFR has more than halved over the past 70 years, from around five children for each female in 1950 to 2.2 children in 2021—with over half of all countries and territories (110 of 204) below the population replacement level of 2.1 births per female as of 2021. This trend is particularly worrying for places such as South Korea and Serbia where the rate is less than 1.1 child for each female. But for many countries in sub-Saharan Africa, fertility rates remain high—the TFR of the region is nearly twice the global average, at four children per female in 2021. In Chad, the TFR of seven births is the highest in the world.
Over the coming decades, global fertility is predicted to decline even further, reaching a TFR of around 1.8 in 2050, and 1.6 in 2100—well below the replacement level. By 2100, only six of 204 countries and territories (Samoa, Somalia, Tonga, Niger, Chad, and Tajikistan) are expected to have fertility rates exceeding 2.1 births per female. In 13 countries, including Bhutan, Bangladesh, Nepal, and Saudi Arabia, rates are even predicted to fall below one child per female.
The TFR in Western Europe is predicted to be 1.44 in 2050, dropping to 1.37 in 2100, with Israel, Iceland, Denmark, France, and Germany expected to have the highest fertility rates at between 2.09 and 1.40 at the end of the century. Rates are projected to be much lower across the rest of Europe and parts of Asia.
Most of the world is transitioning into natural population decline (when the number of deaths exceeds the number of live births); just 26 countries are still projected to be growing in population in 2100 as livebirths continue to outnumber deaths, including Angola, Zambia, and Uganda [1].
“In many ways, tumbling fertility rates are a success story, reflecting not only better, easily available contraception but also many women choosing to delay or have fewer children, as well as more opportunities for education and employment," said Vollset.
Dramatic shifts in the patterns of births – with more than half of live births occurring in sub-Saharan Africa by 2100
In the coming decades, the majority of children will be born in some of the most resource-limited regions of the world, with over three-quarters (77%) of live births expected in low- and lower-middle-income countries by the end of the century.
Fertility decline for many countries in sub-Saharan Africa is occurring at a slower pace, and the region is expected to contribute to over half (54%; around 40 million) of the world’s livebirths by 2100, up from around 41% in 2050, and around a quarter (29%) in 2021.
Much of the anticipated decline in the global share of livebirths will be in the six other super-regions—falling, for example, in South Asia —from around 25% (32 million) in 2021 to 17% (19 million) in 2050 and 7% (5 million) in 2100—but is forecasted to rise modestly in the North Africa and Middle East (from 9% in 2021 to 11% in 2100) and the high-income super-region (8% to 10%).
“A large challenge for countries in sub-Saharan Africa with the highest fertility is to manage risks associated with burgeoning population growth or risk potential humanitarian catastrophe,” said co-lead author and Acting Assistant Professor from IHME Dr. Austin E. Schumacher. “The huge shift in numbers of births underscores the need to prioritise this region in efforts to lessen the effects of climate change, improve health care infrastructure, and continue to reduce child mortality rates, alongside actions to eliminate extreme poverty and ensure that women’s reproductive rights, family planning, and education for girls are top priorities for every government.”
Solutions for a demographically divided world
“These profound changes in future fertility reveal a clear demographic divide between the impacts on many middle-to high-income nations versus many low-income locations that requires national governments to implement safe and beneficial policies to help support conditions that can increase birth rates in some regions and lower them in others,” said Schumacher. “Time is of the essence, as current efforts to manage population growth will likely only be felt after 2050.”
The analysis suggests that concerted efforts to fast-track access to modern contraceptives and female education—the two key drivers of fertility—could help accelerate declines in fertility and reduce birth rates in higher-fertility nations. For example, in sub-Saharan Africa, projections estimate that achieving the UN Sustainable Development Goals for universal female education or universal unmet need for modern contraceptives by 2030 would each result in fertility rates of 2.3 births per woman in 2050 compared with around 2.7 births if these targets aren’t met.
In the highest-fertility countries, the gains could be even greater. In Niger, for example, the total fertility rate is predicted to be five children for each female in 2050. But if the target of universal education were met by 2030, the rate is projected to decline to 2.7 children per female in 2050, while meeting universal contraceptive needs could lower the rate to 4.3 children.
“While achieving both universal targets in all locations by 2030 is likely beyond reach, it’s clear that tackling the population explosion in higher-fertility countries depends greatly on accelerating progress in education for girls and reproductive rights,” said Schumacher.
The study also examined the potential impact that pro-natal policies designed to provide financial support and care for children and families could have on increasing fertility rates in countries with below-replacement fertility. Based on existing information from countries that have already implemented such policies, the findings suggest that while pro-natal policies will not boost fertility rates up to replacement level, they may prevent some countries from dropping to extremely low fertility levels (with just 30 countries and territories below a TFR of 1.3 in 2100 if pro-natal policies are implemented compared to 94 under the most likely scenario). It will be important for low-fertility countries to implement a combination of policies that support those who wish to have children and offer additional benefits to society such as better quality of life and greater participation of women in the workforce, alongside open immigration policies.
“There’s no silver bullet,” said Bhattacharjee. “Social policies to improve birth rates such as enhanced parental leave, free childcare, financial incentives, and extra employment rights, may provide a small boost to fertility rates, but most countries will remain below replacement levels. And once nearly every country’s population is shrinking, reliance on open immigration will become necessary to sustain economic growth. Sub-Saharan African countries have a vital resource that ageing societies are losing—a youthful population.”
She continues, “There is very real concern that, in the face of declining populations and no clear solutions, some countries might justify more Draconian measures that limit reproductive rights. It is well established that nations with strong women's rights are more likely to have better health outcomes and faster economic growth. It is imperative women’s rights are promoted and protected and that women are supported in having the number of children they wish and pursuing their careers.”
The authors note some important limitations, including that while the study uses the best available data, predictions are constrained by the quantity and quality of past data, which was especially limited during the 2020–2021 pandemic period. They also note that past trends are not predictive of what will happen in the future and that these fertility forecasts rely on accurately forecasting each of the potential drivers of fertility into the future.
Writing in a linked Comment, Gitau Mburu, James Kiarie, and Pascale Allotey of the World Health Organization, who were not involved in the study, said, “Fertility is an issue that concerns multiple stakeholders and disciplines. Scientific predictions and policy discourses are essential as we all search for answers. Accurate communication will facilitate better understanding of the issue and informed decisions. Declining TFRs will challenge the global community and could prompt innovations that assist us in achieving sustainable development in the long term.”
NOTES TO EDITORS
Labels have been added to this press release as part of a project run by the Academy of Medical Sciences seeking to improve the communication of evidence. For more information, please see: http://www.sciencemediacentre.org/wp-content/uploads/2018/01/AMS-press-release-labelling-system-GUIDANCE.pdf if you have any questions or feedback, please contact The Lancet press office pressoffice@lancet.com
The study was funded by the Bill & Melinda Gates Foundation. The paper was conducted by the GBD 2021 Fertility and Forecasting Collaborators and researchers at the University of Washington, Seattle, USA.
Quotes from Authors cannot be found in the text of the Article but have been supplied for the press release. The Comment quote is taken directly from the linked Comment.
[1] There is around a 30-year gap between the time when TFR falls below the replacement level (2.1) and when the natural rate of population increase turns negative (i.e., the number of deaths will exceed the number of live births).
Tables - total fertility rates in 2050 and 2100
Top 10 country fertility rates (worldwide) |
|||
2050 |
2100 |
||
Niger (Western sub-Saharan Africa) |
5.15 |
Samoa (Oceania) |
2.57 |
Chad (Western sub-Saharan Africa) |
4.81 |
Tonga (Oceania) |
2.45 |
Somalia (Eastern sub-Saharan Africa) |
4.30 |
Somalia (Eastern sub-Saharan Africa) |
2.45 |
Mali (Western sub-Saharan Africa) |
4.21 |
Niger (Western sub-Saharan Africa) |
2.24 |
South Sudan (Eastern sub-Saharan Africa) |
4.09 |
Chad (Western sub-Saharan Africa) |
2.15 |
Burkina Faso (Western sub-Saharan Africa) |
3.76 |
Tajikistan (Central Asia) |
2.13 |
Afghanistan (North Africa and Middle East) |
3.34 |
Israel (Western Europe) |
2.09 |
Samoa (Oceania) |
3.18 |
Egypt (North Africa and Middle East) |
2.05 |
Benin (Western sub-Saharan Africa) |
3.12 |
Zimbabwe (Southern sub-Saharan Africa) |
2.01 |
Tonga (Oceania) |
3.04 |
South Sudan (Eastern sub-Saharan Africa) |
1.98 |
Lowest 10 country fertility rates (worldwide) |
|||
2050 |
2100 |
||
South Korea (High-income Asia Pacific) |
0.82 |
Bhutan (South Asia) |
0.69 |
Puerto Rico (Caribbean) |
0.84 |
The Maldives (Southeast Asia) |
0.77 |
Taiwan (Province of China) (East Asia) |
0.90 |
Puerto Rico (Caribbean) |
0.81 |
Serbia (Central Europe) |
1.01 |
Nepal (South Asia) |
0.82 |
Ukraine (Eastern Europe) |
1.01 |
South Korea (High-income Asia Pacific) |
0.82 |
Andorra (Western Europe) |
1.02 |
Saint Lucia (Caribbean) |
0.87 |
Saint Lucia (Caribbean) |
1.04 |
Taiwan (province of China) (East Asia) |
0.90 |
Bhutan (South Asia) |
1.07 |
Cabo Verde (Western sub-Saharan Africa) |
0.91 |
The Maldives (Southeast Asia) |
1.07 |
Djibouti (Eastern sub-Saharan Africa) |
0.95 |
Kuwait (North Africa and Middle East) |
1.07 |
Bosnia and Herzegovina (Central Europe) |
0.95 |
Journal
The Lancet
Method of Research
Observational study
Subject of Research
People
Article Title
Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021
Article Publication Date
20-Mar-2024
COI Statement
speakers bureaus, manuscript writing, or educational events and webinars with King Edward Medical University and collaborative partners including University of Johns Hopkins, University of California, and University of Massachusetts; participation on a Data Safety Monitoring Board or Advisory Board with the National Bioethics Committee Pakistan, King Edward Medical University Institutional Ethical Review Board, and the Ethical Review Board Fatima Jinnah Medical University and Sir Ganga Ram Hospital; leadership or fiduciary roles in board, society, committee, or advocacy groups, paid or unpaid, with Pakistan Association of Medical Editors, Fellow of Faculty of Public Health Royal Colleges UK (FFPH), the Society of Prevention, Advocacy and Research of King Edward Medical University (SPARK), and as a Member of the Pakistan Society of Infectious Diseases; and other financial support as Dean of Public Health and Preventive Medicine, King Edward Medical University, as the Chief Editor of Annals of King Edward Medical University since 2014, as the Director of Quality Enhancement Cell, King Edward Medical University, and with the Member Research and Publications Higher Education Commission Pakistan; all outside the submitted work. R Ancuceanu reports consulting fees from AbbVie, Sandoz, B Braun, and Laropharm, all outside the submitted work. J Ärnlöv reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca and Novartis; participation on a Data Safety Monitoring Board or Advisory Board with AstraZeneca, Astella, and Boehringer Ingelheim; all outside the submitted work. M Ausloos reports grants or contracts from the Romanian National Authority for Scientific Research and Innovation, CNDS-UEFISCDI (project number PN-III-P4-ID-PCCF-2016-0084), outside the submitted work. R Bai reports support for the present manuscript from the Social Science Fund of Jiangsu Province (grant number 21GLD008). O C Baltatu reports support for the present manuscript from the National Council for Scientific and Technological Development (CNPq, 304224/2022-7) and from Anima Institute (AI research professor fellowship); leadership or fiduciary roles in board, society, committee, or advocacy groups, paid or unpaid, as a Biotech Board Member at São José dos Campos Technology Park, outside the submitted work. T Bärnighausen reports grants or contracts from the National Institutes of Health (NIH), Alexander von Humboldt Foundation, German National Research Foundation (DFG), EU, German Ministry of Education and Research, German Ministry of the Environment, Wellcome Trust, and KfW; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from PLOS Medicine as the Editor-in-Chief; participation on a Data Safety Monitoring Board or Advisory Board for NIH-funded research projects in Africa on climate change and health; and stock ownership in CHEERS; outside the submitted work. S Barteit reports support for attending meetings or travel from the Wellcome Trust, and stocks or stock options with Climate Change and Health Evaluation and Response System; all outside the submitted work. M L Bell reports grants or contracts from US EPA, NIH, High Tide Foundation, Health Effects Institute, Yale Women Faculty Forum, the Environmental Defense Fund, Wellcome Trust Foundation, Yale Climate Change and Health Center, Robert Wood Johnson Foundation, and the Hutchinson Postdoctoral Fellowship; consulting fees from Clinique; honoraria for lectures, presentations, or speakers bureaus from Colorado School of Public Health, Duke University, University of Texas, Data4Justice, Korea University, Organization of Teratology Information Specialists, UPenn, and Boston University; honorarium for editorial duties from IOP Publishing; honorarium for grant review from NIH, Health Canada, PAC-10, UK Research and Innovation, and AXA Research Fund Fellowship; honorarium for external advisory committee from Harvard University and the University of Montana; support for attending meetings or travel from Colorado School of Public Health, University of Texas, Duke University, Boston University, UPenn, Harvard University, and the American Journal of Public Health; a leadership or fiduciary role in a board, society, committee, or advocacy group, unpaid, with Fifth National Climate Assessment, the Lancet Countdown, Johns Hopkins EHE Advisory Board, a Harvard external advisory committee for training grants, WHO Global Air Pollution and Health Technical Advisory group, and the National Academies Panels and Committees; leadership or fiduciary role in a board, society, committee, or advocacy group, paid, from the US EPA Clean Air Scientific Advisory Committee (CASAC); all outside the submitted work. P J G Bettencourt reports other financial or nonfinancial support as a Project Reviewer at Botnar Foundation; outside the submitted work. P V Bhardwaj reports stock or stock options with Doximity, outside the submitted work. S Bhaskar reports grants or contracts from Japan Society for the Promotion of Science (JSPS), Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT), Grant-in-Aid for Scientific Research (KAKENHI), and JSPS and the Australian Academy of Science (JSPS International Fellowship); leadership or fiduciary roles in board, society, committee, or advocacy groups, paid or unpaid, with Rotary District 9675 as the District Chair, Diversity, Equity, and Inclusion, the Global Health and Migration Hub Community, Global Health Hub Germany (Berlin, Germany) as the Chair and Manager, PLOS One, BMC Neurology, Frontiers in Neurology, Frontiers in Stroke, Frontiers in Public Health, and BMC Medical Research Methodology as an Editorial Board Member; and the College of Reviewers, Canadian Institutes of Health Research (CIHR), Government of Canada as a Member; outside the submitted work. A Biswas reports consulting fees from Lupin Pharmaceuticals (India), Alkem Laboratories (India), and Intas Pharmaceuticals (India); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Roche Diagnostics (India); outside the submitted work. J Conde reports grants or contracts from the European Research Council Starting Grant (ERCStG- 2019-848325), outside the submitted work. S Das reports a leadership or fiduciary role in a board, society, committee, or advocacy group, unpaid, as an executive voluntary member and leadership position in the Association for Diagnostic and Laboratory Medicine and Women in Global Health India Chapter; outside the submitted work. A Dastiridou reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AbbVie and Thea; outside the submitted work. A Faro reports support for the present manuscript from Coordination of Superior Level Staff Improvement (CNPq, Brazil) Productivity in Research Scholarship (PQ Scholarship). A A Fomenkov reports support for the present manuscript from the Ministry of Science and Higher Education of the Russian Federation (theme number 121050500047-5). M Foschi reports consulting fees from Roche, Biogen, Merck, Sanofi, and Novartis; support for attending meetings or travel from Roche, Novartis, Biogen, Sanofi, and Merck; leadership or fiduciary role in a board, society, committee, or advocacy group, paid or unpaid, as a current member of the MSBase collaboration scientific leadership group; outside the submitted work. I Filip reports support for the present manuscript from Avicenna Medical and Clinical Research Institute. I Ilic and M Ilic report support for the present manuscript from the Ministry of Science, Technological Development and Innovation of the Republic of Serbia (grants 451-03-47/2023-01/200111 and 175042, 2011-2023). N E Ismail reports a leadership or fiduciary role in a board, society, committee, or advocacy group, unpaid, with The Bursar as a Council Member of the Malaysian Academy of Pharmacy; outside the submitted work. A Hassan reports consulting fees from Novartis, Sanofi Genzyme, Biologix, Merck, Hikma Pharma, Janssen, Inspire Pharma, Future Pharma, and Elixir Pharma; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Novartis, Allergan, Merck, Biologix, Janssen, Roche, Sanofi Genzyme, Bayer, Hikma Pharma, Al Andalus, Chemipharm, Lundbeck, Inspire Pharma, Future Pharma and Habib Scientific Office, and Everpharma; support for attending meetings or travel from Novartis, Allergan, Merck, Biologix, Roche, Sanofi Genzyme, Bayer, Hikma Pharma, Chemipharm, Al Andalus Pharmaceuticals, and Clavita Pharmaceuticals; a leadership or fiduciary role in a board, society, committee, or advocacy group, paid or unpaid, as a member of educational, membership, and regional committees of international headache societies; outside the submitted work. C Herteliu reports grants or contracts from the Romanian Ministry of Research Innovation and Digitalization (MCID, project number ID-585-CTR-42- PFE-2021), a grant of the European Commission Horizon 4P-CAN Personalised Cancer Primary Prevention Research through Citizen Participation and Digitally Enabled Social Innovation Project “Societal and Economic Resilience within multi-hazards environment in Romania” funded by EU—NextgenerationEU and Romanian Government, under National Recovery and Resilience Plan for Romania (contract number 760050/23.05.2023, cod PNRR-C9-I8-CF 267/29.11.2022), through the Romanian Ministry of Research, Innovation and Digitalization, within Component 9, Investment I8, and Project “A better understanding of socio-economic systems using quantitative methods from Physics’’ funded by EU—NextgenerationEU and Romanian Government, under National Recovery and Resilience Plan for Romania (contract number 760034/23.05.2023, cod PNRR-C9-I8-CF 255/29.11.2022), through the Romanian Ministry of Research, Innovation and Digitalization, within Component 9, Investment I8; outside the submitted work. T Joo reports support for the present manuscript from the National Research, Development and Innovation Office in Hungary (RRF-2.3.1-21-2022-00006), Data-Driven Health Division of National Laboratory for Health Security. J Jozwiak reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Novartis, ADAMed, and Amgen, outside the submitted work. J H Kempen reports support for the present manuscript from Sight for Souls and the Mass Eye and Ear Global Surgery Program; participation on a Data Safety Monitoring Board or Advisory Board with Gilead; leadership or fiduciary role in a board, society, committee, or advocacy group, unpaid, on the board of Sight for Souls; stock or stock options with Betaliq and Tarsier; outside the submitted work. K Krishan reports other non-financial support from the UGC Centre of Advanced Study, CAS II, awarded to the Department of Anthropology, Panjab University (Chandigarh, India); outside the submitted work. B Lacey reports support for the present manuscript from UK Biobank, funded largely by the UK Medical Research Council and Wellcome Trust. J Lam reports support for the present manuscript from the National Research, Development and Innovation Fund (project number TKP2021-NVA-11). H J Larson reports grants or contracts from GSK and Moderna; consulting fees from the Gates Medical Research Institute and Apiject; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events as a 2022 Merrimon Lecturer (UNC); outside the submitted work. M Lee reports support for the present manuscript from the Ministry of Education of the Republic of Korea and the National Research Foundation of Korea (NRF- 2021R1I1A4A01057428) and Bio-convergence Technology Education Program through the Korea Institute for Advancement Technology (KIAT) funded by the Ministry of Trade, Industry and Energy (P0017805). M-C Li reports grant support from the National Science and Technology Council in Taiwan (NSTC 112-2410-H-003-031); leadership or fiduciary role in a board, society, committee or advocacy group, paid or unpaid, as the Technical Editor of the Journal of the American Heart Association. M A Mahmoud reports grants or contracts from Deputyship for Research & Innovation, Ministry of Education in Saudi Arabia for funding this research work through the project number 445-5-762; outside the submitted work. R J Maude reports support for the present manuscript from Wellcome Trust (grant number 220211) because it provides core funding for Mahidol Oxford Tropical Medicine Research. A-F A Mentis reports grants or contracts from MilkSafe: a novel pipeline to enrich formula milk using omics technologies, a research co-financed by the European Regional Development Fund of the EU and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH–CREATE–INNOVATE (project code T2EDK-02222), as well as from ELIDEK (Hellenic Foundation for Research and Innovation, MIMS-860), both outside of the present manuscript; payment or expert testimony as a peer reviewer for Fondazione Cariplo, Italy; participation on a Data Safety Monitoring Board or Advisory Board as Editorial Board Member for Systematic Reviews and Annals of Epidemiology, and as Associate Editor for Translational Psychiatry; stock or stock options on a family winery; other financial interests as a scientific officer as part of the BGI Group; outside the submitted work. P B Mentis reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Janssen (Australia) and Sanofi (Hangzhou); participation on a Data Safety Monitoring Board or Advisory Board from Janssen (Australia); outside the submitted work. L Monasta and L Ronfani report support for the present manuscript from the Italian Ministry of Health (Ricerca Corrente 34/2017) via payments made to the Institute for Maternal and Child Health Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Burlo Garofolo. R S Moreira reports grants or contracts from the National Council for Scientific and Technological Development CNPq Research Productivity Scholarship (scholarship registration number 316607/2021-5). J Morze reports grants or contracts from SciLifeLab and Wallenberg Data Driven Life Science Program (KAW 2020.0239); consulting fees from ALAB Laboratoria; outside the submitted work. S Muthu reports leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, on the NEXTGen Committee (ICRS), Grants Committee (SICOT), and with the Knowledge Forum Degenerative Associate as a member (AO Spine); outside the submitted work. S Nomura reports support for the present manuscript from the Ministry of Education, Culture, Sports, Science and Technology of Japan (21H03203) and Precursory Research for Embryonic Science and Technology from the Japan Science and Technology Agency (JPMJPR22R8). A P Okekunle reports support for the present manuscript from the National Research Foundation of Korea funded by the Ministry of Science and ICT (2020H1D3A1A04081265); support for attending meetings or travel from the National Research Foundation of Korea funded by the Ministry of Science and ICT (2020H1D3A1A04081265), outside the submitted work. A Pantea Stoian reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Eli Lilly, Merck, Medtronic, Novo Nordisk, Servier, and Sanofi; support for attending meetings or travel from Sanofi, Novo Nordisk, and Eli Lilly; participation on a Data Safety Monitoring Board or Advisory Board with Eli Lilly, Novo Nordisk, and Sanofi; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, as the Vice-president of the Central European Diabetes Association and as the President of the Romanian National Diabetes Committee; outside the submitted work. R Passera reports participation on a Data Safety Monitoring Board or Advisory Board as the expert biostatistician member for the clinical trial Consolidation with ADCT-402 (loncastuximab tesirine) after immunochemotherapy: a phase II study in BTKi-treated/ineligible Relapse/Refractory Mantle Cell Lymphoma (MCL) patients, sponsor FIL, Fondazione Italiana Linfomi, Alessandria-I; outside the submitted work. M Pigeolet reports grants or contracts from the Belgian Kids’ Fund for Pediatric Research; outside the submitted work. A E Peden reports support for the present manuscript from the Australian National Health and Medical Research Council (grant number APP2009306). V C F Pepito reports grants or contracts from Sanofi Consumer Healthcare and International Initiative for Impact Evaluation; outside the submitted work. A Radfar reports support for the present manuscript from Avicenna Medical and Clinical Research Institute. A Rane reports support for the present manuscript from The Bill & Melinda Gates Foundation; stock or stock options as a full-time employee of Agios Pharmaceuticals; outside the submitted work. J Sanabria reports a pending grant award from the NIH, National Cancer Institute (NCI), and DoD; support for attending meetings or travel from Marshall University Medical School; three patents pending; participation on a Data Safety Monitoring Board or Advisory Board as the Chair of quality assessment and assurance for the Marshall University Department of Surgery; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid with the American Society of Transplant Surgeons, the American Association for the Study of Liver Diseases, International Hepato-Pancreato Biliary Association, the Americas Hepato-Pancreato-Biliary Association, the Society for Surgery of the Alimentary Tract, and the Society of Surgical Oncology; outside the submitted work. N Scarmeas reports grants or contracts from Novo Nordisk; participation on a Data Safety Monitoring Board or Advisory Board with the NIH; outside the submitted work. A Sharifan reports leadership or fiduciary role in other board, society, committee, or advocacy group, unpaid, with Cochrane as a steering member of the Cochrane Early Career Professionals Network; receipt of equipment, materials, drugs, medical writing, gifts, or other services from Elsevier; outside the submitted work. V Sharma acknowledges support from DFSS (MHA)’s research project (DFSS28[1]2019/EMR/6) at Institute of Forensic Science and Criminology, Panjab University (Chandigarh, India); outside the submitted work. V Shivarov reports one patent and one utility model with the Bulgarian Patent Office; stock or stock options from ICONplc (RSUs); and other financial interests from an ICONplc salary; outside the submitted work. J P Silva reports support for the present manuscript from the Portuguese Foundation for Science and Technology. J A Singh reports consulting fees from AstraZeneca, Crealta/Horizon, Medisys, Fidia, PK Med, Two Labs, Adept Field Solutions, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, and Practice Point Communications; and the NIH and the American College of Rheumatology; payment for lectures, presentations, speakers bureaus, manuscript writing, or educational events as a member of the speakers bureau Simply Speaking; support for attending meetings or travel as a past steering committee member of OMERACT; participation on a Data Safety Monitoring Board or Advisory Board for the FDA Arthritis Advisory Committee; leadership or fiduciary role in a board, society, committee, or advocacy group, paid or unpaid, as a past steering committee member of the OMERACT, an international organisation that develops measures for clinical trials and receives arm’s length funding from 12 pharmaceutical companies, as Co-Chair of the Veterans Affairs Rheumatology Field Advisory Committee, and as Editor and Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis; stock or stock options in Atai Life Sciences, Kintara Therapeutics, Intelligent Biosolutions, Acumen Pharmaceutical, TPT Global Tech, Vaxart Pharmaceuticals, Atyu Biopharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics, Seres Therapeutics, Tonix Pharmaceuticals Holding, and Charlotte’s Web Holdings, and previously owned stock options in Amarin, Viking, and Moderna Pharmaceuticals; outside the submitted work. M V Titova reports support for the present manuscript from the state assignment of the Ministry of Science and Higher Education of the Russian Federation (theme number 121050500047-5). H Zhang reports grants or contracts from World Health Organization (WHO) funding; outside the submitted work. M Zielinska reports other financial support as an AstraZeneca employee; outside the submitted work. All other authors declare no competing interests. Data sharing To download the data used in these analyses, please visit the Global Health Data Exchange GBD 2021 website (http://ghdx.healthdata.org/ gbd-2021/sources). Acknowledgments Research reported in this publication was supported by the Bill & Melinda Gates Foundation, the UK Department of Health and Social Care, the Norwegian Institute of Public Health, and the New Zealand Ministry of Health. The Palestinian Central Bureau of Statistics granted the researchers access to relevant data in accordance with licence number SLN2019-8-64, after subjecting data to processing aiming to preserve the confidentiality of individual data in accordance with the General Statistics Law, 2000. The researchers are solely responsible for the conclusions and inferences drawn upon available data. This analysis uses data or information from the LASI Pilot micro data and documentation. The development and release of the LASI Pilot Study was funded by the National Institute on Ageing, NIH (R21AG032572, R03AG043052, and R01 AG030153), the Russia Longitudinal Monitoring survey, RLMS-HSE, conducted by the National Research University Higher School of Economics and ZAO Demoscope together with Carolina Population Center, University of North Carolina at Chapel Hill and the Institute of Sociology RAS. We would like to thank Statistics Botswana and the Directorate of National Statistics, Somalia, for data presented in this publication. Editorial note: The Lancet Group takes a neutral position with respect to territorial claims in published maps, tables, and institutional affiliations.